Introduction: Interleukin-34 (IL-34) is a recently defined cytokine, showing a functional overlap with macrophage colony stimulating factor (M-CSF). This study was undertaken to address the expression of IL-34 in rheumatoid arthritis (RA) patients and to investigate its regulation and pathogenic role in RA.
Introduction
Rheumatoid arthritis (RA) is an autoimmune chronic inflammatory disease characterized by bone and cartilage destruction that is mediated by bone-resorbing osteoclasts (OCs) [1, 2] . OCs differentiate from the monocyte/macrophage lineage of hematopoietic myeloid progenitors in response to macrophage colony-stimulating factor (M-CSF) and RANKL (receptor activator of NF-B ligand) [3, 4] and participate in a variety of inflammatory bone degenerative diseases. OC differentiation correlates with the severity of the inflammatory condition [2] . OCs mediate erosive bone resorption at the bone-pannus interface of the synovium in RA joints resulting from chronic inflammation of multiple synovial joints [5] . Synovial fluid (SF) produced by the inflamed synovium in joints, hyperplasic synovial fibroblasts, and activated synovial T cells increases the production of RANKL and several inflammatory cytokines [6, 7] . These inflammatory conditions lead to enhanced OC formation and the subsequent increase in resorbing activity [2] .
Tumor necrosis factor alpha (TNFα) is well established as a critical OC differentiation-enhancing factor that acts by mediating mobilization of osteoclast precursors (OCPs) from bone marrow into the inflamed joint, where they appear to contribute to inflammatory erosive arthritis [8] . TNFα-stimulated fibroblast-like synovial cells (FLS) increase cytokine production [6] , which accelerates OC formation in the inflamed synovium of RA [9] . Thus, the administration of TNFα blocking agents results in a decrease in the pathological changes indicative of RA inflammatory responses, and as such provides a potential clinical benefit [10] . Recent studies have shown that administration of an antibody (Ab) against the M-CSF receptor, c-Fms or inhibitor, selectively and completely blocks osteoclastogenesis and bone erosion induced by TNFα injection or inflammatory arthritis [11, 12] , suggesting a link between TNFα and c-Fms under pathological inflammatory conditions. Accordingly, identifying factors involved in TNFα-induced OCPs mobilization and subsequent differentiation that contribute to erosive arthritis is a matter of considerable interest.
The recently discovered cytokine IL-34 binds to the M-CSF receptor c-Fms [13] . The functional similarity of IL-34 and M-CSF is demonstrated by their role in osteoclastogenesis [14] [15] [16] [17] [18] . Although IL-34 and M-CSF share the c-Fms receptor, their signal transduction mechanisms and biological activity are not identical [16] . Functional overlap [16] , but differential expression, of M-CSF and IL-34 has been observed in the context of M-CSF receptor-mediated regulation of myeloid cells [18] . However, whether IL-34 is involved in RA pathogenesis is still unknown.
Materials and methods

Patients and reagents
All RA patients enrolled in this study fulfilled the 1987 revised criteria of the American College of Rheumatology [19] . Patients were compared with age-and sexmatched control patients with OA.
Informed consent was obtained from all patients and the experimental protocol was approved by the Human Research Ethics Committee of the University of Ulsan College of Medicine (2010-871). SF was collected from the knee joint (with or without swelling) of each patient by sterile aspiration and centrifuged at 250g for 10 minutes. Cell-free RA synovial fluid (RA SF) was stored at -70°C until used. Synovia were isolated from seven patients with RA (mean age, 59.9 ± 12.3; range, 42 to 75 years) and seven patients with OA (mean age, 62.5 ± 8.2; range, 46 to 77 years). All patients were undergoing knee replacement surgery. For the one-year follow-up study, sera were collected from the patients listed in Additional file 1 at baseline and one year after treatment from ten patients with RA. RA activity was simultaneously assessed using Disease Activity Score 28 (DAS28) activity [20] .
Pyrrolidine dithiocarbamate (PDTC), SP600125, SB203580, PD98059, and anti-β-actin antibody was purchased from Sigma (St. Louis, MO, USA). Rabbit antihuman IL-34 for immunoblotting was from ProSci Incorporated (Poway, CA, USA). Mouse anti-human IL-34 for blocking IL-34 activity, mouse polyclonal immunoglobulin G (IgG), IL-17, TNFα, and IL-1β were purchased from R&D Systems (Minneapolis, MN, USA). Recombinant M-CSF, RANKL, and IL-34 were purchased from PeproTech, Inc. (Rocky Hill, NJ, USA).
Immunohistochemistry
OA and RA synovia for immunohistochemistry analysis were collected in accordance with experimental protocols approved by the Stanford University Institutional Review Board and with the patients' informed consent as described [12] . Sections of optimal cutting temperature (OCT) compound-embedded synovial tissue samples were cut on a cryostat (Thermo Scientific, Kalamazoo, MI, USA) and fixed in 4% paraformaldehyde for 10 minutes at 4°C. The slides were then washed twice (5 minutes each) with PBS and permeabilized with 0.1% Triton X-100 for 3 minutes at room temperature. After washing with PBS, endogenous peroxidase activity was quenched with 0.03% H 2 O 2 solution. The slides were blocked with 7.5% normal goat serum for 20 minutes and thereafter incubated with 4 μg/ml of IL-34 antibody (LSBio, Seattle, WA, USA) or control rabbit IgG (Abcam, Cambridge, MA, USA) for 20 minutes at room temperature. Following two washes with PBS, the slides were incubated with 1:200 diluted biotinylated secondary antibody (Vectastain EliteABC Kit; Vector Laboratories, Orton Southgate, Peterborough, UK) for 30 minutes. After washing with PBS, the slides were incubated with complexed avidin-biotin horseradish peroxidase ABC reagent (Vectastain Elite ABCkit; Vector) for 30 minutes, and then exposed to 3,3-diaminobenzidine (DAB) substrate according to the manufacturer's instructions (Vector). The nuclei were subsequently counterstained with hematoxylin (Vector). Tissues were examined and photographed with an Olympus BX51 microscope outfitted with an Olympus DP72 digital camera (Olympus).
Isolation of FLS and OCPs from human peripheral blood mononuclear cells (PBMCs)
FLS were isolated by enzymatic digestion of synovial tissues obtained from RA and OA patients undergoing total joint replacement surgery, as previously described [21] . Blood was collected from healthy volunteers and PBMCs were obtained from whole blood by centrifugation over Ficoll gradients (Pharmacia Biotech, Uppsala, Sweden) at 400g for 30 minutes and erythrocytes were removed by lysing in ACK buffer (0.15 M NH 4 Cl, 1 mM KHCO 3 and 0.1 mM EDTA, pH 7.2).
Conventional reverse transcriptase-polymerase chain reaction (RT-PCR) PCR and quantitative real-time RT-PCR Total RNA was extracted from synovial tissues obtained from three RA patients, as indicated, using the RNeasy Mini Kit (QIAGEN, Hilden, Germany). cDNA was synthesized from total RNA using murine Moloney leukemia virus reverse transcriptase (MMTV-RT, Gibco BRL, Gaithersburg, MD, USA). The cDNA was amplified using the Takara PCR amplification kit (Takara Biotechnology, Shiga, Japan); PCR was carried out in a Perkin Elmer thermal cycler. Quantitative RT-PCR (qRT-PCR) was performed using Power SYBR Green 1-
Step Kit and an ABI 7000 Real Time PCR System (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer's instructions. The sequences of primers used were as follows: IL-34, 5'-TAC AGG AGC CGA CTT CAG-3' (sense) and 5'-CTC ACC AAG ACC CAC AGA-3' (antisense); M-CSF, 5'-GCT GCT TCA CCA AGG ATT ATG-3' (sense) and 5'-GGG TCA CTG CTA GGG ATG-3' (antisense); and GAPDH (glyceraldehyde 3-phosphate dehydrogenase), 5'-AGC CAC ATC GCT CAG ACA-3' (sense) and 5'-GCC CAA TAC GAC CAA ATC C-3' (antisense). Results are expressed as the ratio of target PCR product relative to GAPDH product. The amplification protocol consisted of an initial reverse transcription step at 48°C for 30 minutes, followed by 40 cycles of denaturation at 95°C for 15 seconds and annealing and extension at 60°C for 1 minute.
Enzyme-linked immunosorbent assay (ELISA)
IL-34 concentration was measured using an IL-34-specific sandwich ELISA (R&D systems, Minneapolis, MN, USA) in accordance with the protocols of the manufacturer. Recombinant human IL-34 serially diluted in culture media was used as a standard. ELISA plates were incubated with mouse anti-human IL-34 Ab and then blocked with 3% BSA in PBS for 1 hour at room temperature. SF from patients with RA and OA, or supernatants from FLS cultures were added to the plates. After washing with PBS containing 0.05% Tween 20, each well was incubated with biotinylated mouse anti-human IL-34 (0.5 μg/ml) for 2 hours at room temperature. Plates were then washed with PBS containing 0.05% Tween 20 and incubated with streptavidin conjugated to horseradish peroxidase (HRP) for 1 hour at room temperature. A color reaction was developed with tetramethylbenzidine solution, and then stopped with 0.1 M H2SO4. The absorbance at 450 nm was measured using a Bio-Rad microtiter plate reader (Bio-Rad Laboratories, Hercules, CA, USA).
Immunoblotting
RA FLS were collected and proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose paper (GE Healthcare, Piscataway, NJ, USA). The membranes were immunoblotted with an anti-human IL-34 rabbit polyclonal IgG or β-actin antibody. Bound antibodies were visualized with HRP-conjugated antibodies against rabbit or mouse IgG using an enhanced chemiluminescence Western blotting system (Millipore, Billerica, MA, USA).
PBMCs migration assay
Transmigration assays were performed as follows using PBMCs: conditioned media (CM) was prepared by collecting supernatant from RA FLS cultured in the presence of TNFα (10 ng/ml) for 24 hours. CM from RA FLS cultures, recombinant IL-34 (100 ng/ml), or CM plus anti-IL-34 Ab was added to the lower compartments of a 5-μm pore Transwell system (Costar, Corning, NY, USA). PBMCs (1.2 × 10 6 ) were added to the upper chamber of each transwell and allowed to migrate for 6 hours. The number of PBMCs in the lower chamber was then counted.
OC differentiation
For osteoclastogenesis, PBMCs were plated on 48-well plates and cultured in α-MEM supplemented with 10% fetal bovine serum (FBS) and cultured with RANKL (100 ng/ml) plus M-CSF (100 ng/ml) as a control as described [21] or RANKL (100 ng/ml) plus IL-34 (100 ng/ml). RANKL was added at a final concentration of 100 ng/ml to CM obtained from RA FLS cultured in the presence of TNFα (10 ng/ml) for 24 hours. Osteoclastic differentiation was maintained for 12 to 14 days prior to tartrate resistant acid phosphatase (TRAP) staining and scoring of multinucleated OCs, as previously described [22] .
Statistical analysis
Means ± standard deviations (SDs) were calculated for all conditions, and differences between means were analyzed using Student's t-test. A P-value < 0.05 was considered significant. Patient data were tested by the Mann-Whitnney U test.
Results
High levels of IL-34 in synovia and SF from patients with RA
To demonstrate the involvement of IL-34 in RA pathogenesis, we first determined whether synovia and SF from patients with RA (RA SF) displayed high levels of IL-34. IL-34 mRNA expression was detected in synovia obtained from three RA patients at levels similar to those of M-CSF ( Figure 1A) ; high levels of IL-34 mRNA ( Figure 1A ) and protein ( Figure 1B) were observed in human RA synovium compared to OA synovium. The levels of IL-34 protein in RA SF were comparable to those of M-CSF ( Figure 1C ). In addition, we found that IL-34 protein was expressed in FLS from RA patients ( Figure 1D ). These observations indicate that IL-34 is expressed in synovial tissue, synovial fluid, and FLS from RA patients, suggesting that IL-34 is an additional factor involved in the pathogenesis of RA.
TNFa-induced IL-34 production by FLS of RA patients FLS act as the main cell mediating the cytokine-rich environment of the inflamed synovium in RA pathogenesis [23] and stimulate OC differentiation and activity in the inflammatory bone destruction by regulating RANKL expression [24, 25] . Interestingly, we found that the level of soluble IL-34 in RA SF from inflamed RA synovium (351.7 ± 30.7 pg/ml) with joint swelling was significantly higher than that in RA SF from non-inflamed RA synovium (81.1 ± 24.5 pg/ml; P < 0.01) (Figure 2A ). We therefore determined whether RA FLS produced IL-34 in response to pro-inflammatory cytokines. RA FLS (n = 9) or OA FLS (n = 4), used as a disease control, were cultured with TNFα, IL-1β, or IL-17 (each at 10 ng/ml) for 24 hours. Interestingly, the increase in IL-34 concentration was more marked in TNFα-stimulated RA FLS than in IL-1β-or IL- Figure 2B ). In contrast, OA FLS showed no significant changes in those responses ( Figure  2B) . Moreover, an analysis of IL-34 mRNA levels using quantitative real-time RT-PCR showed that IL-34 mRNA expression was markedly increased in TNFα-stimulated RA FLS compared to controls (P < 0.01) ( Figure 2C ). IL-1β and IL-17 treatment induced a smaller increase in IL-34 mRNA expression ( Figure 2C) . However, the level of IL-34 expression in control OA FLS was not significantly modulated by these cytokines ( Figure 2C ). These results provide the first demonstration that RA FLS produce IL-34 and that this production is enhanced by TNFα.
17-stimulated RA FLS (
Differential induction of IL-34 by RA FLS treated with TNFa
IL-34 and M-CSF were recently reported to share the same receptor, c-Fms [13] . Our data showed that IL-34 expression was enhanced after treatment with TNFα Figure 2 ), suggesting that differential production of IL-34, regulated by the pathological condition of RA, can replace M-CSF function. To test this possibility, we next examined whether TNFα differentially regulates IL-34 and M-CSF expression. RA FLS constitutively expressed and produced both M-CSF and IL-34 ( Figure 3A) . TNFα treatment caused a 12-fold increase in IL-34 mRNA expression above this basal level ( Figure 3A , right), but had little effect on M-CSF mRNA expression ( Figure 3A, left) . Together, the level of IL-34 protein in RA FLS was much greater than M-CSF production in the presence of TNFα (Figure 3B) , showing approximately a 1.5-fold increase in TNFα-treated RA FLS over that of the control RA FLS ( Figure 3C ). Thus, these data demonstrate the differential regulation of IL-34 and M-CSF expression by TNFα.
TNFα activates NF-B and JNK, which are important for TNFα-mediated gene expression and are involved in the activation of FLS [26] . To understand better the mechanism by which TNFα increases IL-34 production in RA FLS, we examined the effects of inhibitors of NF-B or JNK on IL-34 expression. RA FLS were pretreated with the vehicle, NF-B inhibitor, PDTC, or the JNK inhibitor, SP600125, at a concentration of 10 μM for 30 minutes followed by incubation with TNFα for 24 hours. As shown in Figure 3D , the NF-B inhibitor, PDTC, effectively reduced TNFα-induced IL-34 mRNA expression; moreover, JNK inhibition modestly decreased the TNFα-induced elevation of IL-34. However, p38 or extracellular signal-regulated protein kinase (ERK) inhibition did not affect TNFα-induced IL-34 mRNA expression ( Figure 3D ). Collectively, these results suggest that the TNFα-induced increase in IL-34 expression in RA FLS is mediated by NF-B and JNK pathways.
Clinical determination of IL-34 in plasma from patients with RA
Given that IL-34 is up-regulated in inflamed synovium and in RA FLS in response to TNFα, (Figure 2 ) the levels of IL-34 may reflect the pathogenesis of inflammation in RA patients. To explore this correlation, we performed a comparative analysis of plasma IL-34 levels in RA patients (n = 10) using ELISAs. The patients with RA had higher plasma IL-34 levels than normal or OA controls ( Figure 4A) . One group of patients with rheumatoid arthritis, defined by a plasma DAS28 score at baseline of 2.9 to 7.4, had undergone a 1-year follow-up treatment with DMARDs, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine. Patients in this group (n = 10) showed an apparent decrease in DAS28 score of approximately 50% (to 1.7 to 3.4) after taking DMARDs ( Figure 4B ). Importantly, high levels of soluble IL-34 (6.573 ± 2.003 ng/ml) were detected in plasma from RA patients before DMARDs treatment ( Figure 4C ). However, a significant decrease (P < 0.01) in plasma IL-34 levels was observed after taking DMARDs in this group ( Figure 4C ). These data suggest that the plasma level of IL-34 correlates with the level of inflammation in RA patients.
Effect of IL-34 on PBMCs migration and subsequent OC formation
Having shown that RA FLS produce IL-34 ( Figure 2A  and 3) , we thus questioned whether IL-34 produced by RA FLS has functional activities to induce chemotactic migration of OCPs and to subsequently induce osteoclastogenesis as a substitute for M-CSF in RANKLinduced osteoclastogenesis. Human PBMCs as OCPs [27] Figure 5C ). These data demonstrate that IL-34 secreted by RA FLS is functionally active enough to stimulate the chemotactic migration of OCPs and subsequent OC formation.
Discussion
Although RANKL is absolutely required for OC differentiation in vivo [28, 29] , several cytokines, including vascular endothelial growth factor and hepatocyte growth factor, can be substituted for M-CSF in promoting osteoclastogenesis [30] [31] [32] . The inflamed synovium of RA patients is the major source of overproduction of cytokines, and these cytokines may contribute to osteoclastic activation [33] ; thus, understanding the specific RA FLS were pretreated with the vehicle (dimethyl sulfoxide, 10 μM), NF-B inhibitor, pyrrolidine dithiocarbamate(10 μM), the JNK inhibitor, SP600125 (10 μM), the p38 inhibitor, SB203580 (10 μM), or the extracellular signal-regulated protein kinase (ERK) inhibitor, PD98059 (10 μM), for 30 minutes and then treated with 10 ng/ml TNFα for 24 hours. Untreated RA FLS were used as a control (none). M-CSF and IL-34 mRNA levels were determined in cell lysates by qRT-PCR. The relative expression of IL-34 mRNA is presented as fold change in gene expression compared to untreated vehicle controls (*P < 0.05, N.S., not significant, compared to veh). none, no treatment; veh, vehicle; SP, SP600125; SB, SB203580; PD, PD98059.
factors capable of replicating the effect of M-CSF is of considerable research interest.
Inflammatory cytokines, including IL-1β, IL-17 and TNFα, are elevated in the SF of RA patients [34] and are known to stimulate osteoclastogenesis through induction of M-CSF [35] [36] [37] . In this study, we demonstrated that both IL-34 mRNA and protein expression were up-regulated by TNFα to a greater extent in RA FLS than in OA FLS, a pattern distinct from that of M-CSF expression (Figure 2) . Thus, this is the first report describing the stimulation of IL-34 expression by TNFα in FLS of RA patients, suggesting that RA FLS are much more susceptible to the production of IL-34 than M-CSF in response to TNFα. Further study implies a discrete role of IL-34 in the pathological inflammatory setting of RA.
A recent report demonstrated that TNFα induces IL-34 mRNA via JNK and NF-B, but not the p38 pathway, in osteoblasts [38] . NF-B, in particular, is responsible for TNFα-induced M-CSF expression in primary osteoblast cells [39] . In our experiments, TNFα-mediated induction of IL-34 expression was inhibited by an NF-B inhibitor, indicating that IL-34 expression is regulated, at least in part, by NF-B. Moreover, JNK inhibition modestly decreased the elevation of IL-34 expression, indicating that JNK may also be involved in IL-34 expression in FLS of RA patients ( Figure 3D ).
Several combinations of DMARDs used for the treatment of arthritis conditions [40] , such as RA or psoriatic arthritis (PsA), have been demonstrated to abrogate inflammation [41] . IL-34 was detected in plasma samples of RA patients and it was effectively reduced by DMARDs treatment in RA patients ( Figure 4A ). Our data provide an initial indication of the importance of the clinical correlation between plasma IL-34 levels and inflammatory responses in RA patients, suggesting the significance of IL-34 as a plasma factor in RA patients representing inflammatory arthritis in the pathogenesis of RA. In our study population, individual variations in combination therapy were not controlled; thus, additional clinical studies with a larger number of patients divided into subgroups is needed to validate the clinical implications of elevated IL-34 in the pathogenesis of RA.
IL-34, like M-CSF, has been shown to promote osteoclastogenesis in combination with RANKL [14, 18] and induce bone resorption activity [18] . We also found that IL-34 produced from TNFα-stimulated RA-FLS promoted chemotactic migration of human PBMCs and RANKL-induced osteoclastogenesis ( Figure 5 ), demonstrating a biologically active function of IL-34. Therefore, TNFα-stimulated up-regulation of IL-34 in RA FLS may play a pathological role in RA, possibly at the site of inflammatory erosive bone resorption and local bone destruction. In PsA, an inflammatory joint disease characterized by extensive bone resorption, OCPs arise from TNFα-activated PBMCs that migrate to the inflamed synovium and subchondral bone, where they are exposed to unopposed RANKL and TNFα [42] . This leads to osteoclastogenesis at the erosion front and in subchondral bone, resulting in a bidirectional assault on psoriatic bone [42] . A recent report showed that M-CSF levels are not elevated in SF from patients with PsA to the same extent as in RA patients [12] . Accordingly, IL-34 may replace this M-CSF function and contribute to the pathogenesis of PsA; however, the role of IL-34 in PsA remains to be investigated.
Genetic ablation of M-CSF in op/op (M-CSF-deficient) mice and inhibition of M-CSF by administration of anti-M-CSF mAbs exerts protective effects in a number of inflammatory and/or autoimmune conditions [43, 44] . Moreover, blocking c-Fms inhibits macrophage infiltration, TNFα production by macrophages, and OC Figure 4 Correlation between interleukin-34 (IL-34) levels and inflammation in rheumatoid arthritis (RA) patients. (A) IL-34 levels were determined in plasma of healthy controls (normal), OA or RA patients by n enzyme-linked immunosorbent assay (ELISA) (*P < 0.05, N.S., not significant, compared to normal). (B) and (C) Plasma was collected from individual RA patients (n = 10) and the same patients were administrated disease-modifying anti-rheumatic drugs (DMARDs) and followed-up for 1 year. Disease Activity Score 28 (DAS28) activity (A) and IL-34 levels (ELISA) (B) were determined for each patient in plasma samples collected before and after administration of DMARDs. Symbols indicate individual data points; horizontal bars show group means (P < 0.01, after versus before DMARDs administration).
formation and activation in several mouse arthritis models [12, 45] , and reduces TNFα-induced inflammatory arthritis [11] , suggesting a therapeutic benefit in RA treatment. The increase in IL-34 in RA reported here supports the concept that IL-34 regulates OCP migration and subsequent OC differentiation, suggesting the possibility that IL-34 can functionally substitute for M-CSF and is involved in the RA disease process elicited by TNFα. It is important to note in this context that elevated IL-34 in RA SF can activate c-Fms, even in the absence of M-CSF. Thus, inhibiting c-Fms may be a more promising strategy than targeting M-CSF in the treatment of RA where the disease pathogenesis involves TNFα.
Conclusions
We propose that IL-34 is elevated in RA SF and is produced by RA FLS. IL-34 expression is enhanced by TNFα through the NF-B and JNK pathway and is a biologically active stimulator of OC differentiation that exerts synergistic effects with RANKL. Further investigations to define the pathological implications of this cytokine in osteolysis in vivo are warranted.
Additional material
Additional file 1: Characteristics of patients with rheumatoid arthritis (RA). All patients were 30 years or older at the time of RA diagnosis and their mean ± SD age was 53.3 ± 16.0 years. All patients were positive for rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibody and had a diagnosis of RA with a median baseline Disease Activity Score 28 (DAS28) of 5.27 (range 2.9 to 7.4), a median 1 year DAS28 of 2.58 (1.7 to 3.4), a baseline median erythrocyte sedimentation rate of 69.6 (28 to 120), and a median baseline C-reactive protein (CRP) of 1.05 (0.1 to 2.04). With regard to medications used for the treatment of RA, patients were treated with prednisolone and disease-modifying antirheumatic drugs (DMARDs) including methotrexate, sulfasalazine, leflunomide, FK506, and/or hydroxychloroquine. SD, standard deviation. performed statistical analysis on the patients' plasma samples. EC designed the study, contributed to data analysis, and wrote the manuscript. All authors have read and approved the final manuscript.
